ATP13A9 (ATPase Cation Transporting 13A9) is a gene located on chromosome 9p21 that encodes a P5-type ATPase protein primarily expressed in the brain. Variants in ATP13A9 have been associated with an increased risk of Parkinson's disease through genome-wide association studies (GWAS)[1]. The gene is highly expressed in dopaminergic neurons of the substantia nigra and is involved in lysosomal function, metal ion transport, and cellular stress responses.
ATP13A9 belongs to the P5 ATPase family, which are cation transporters belonging to the larger P-type ATPase superfamily. These enzymes utilize ATP hydrolysis to transport cations across cellular membranes against concentration gradients. The P5 subfamily is unique among P-type ATPases in its preference for transition metals and its predominantly intracellular localization[2].
The protein consists of multiple transmembrane domains that form a channel for cation transport, coupled with cytoplasmic domains that bind ATP and facilitate phosphorylation of an aspartate residue during the transport cycle. Unlike other P-type ATPases, ATP13A9 lacks the canonical heavy metal-binding domains found in P1B-type ATPases, suggesting it may have distinct substrate specificities[3].
ATP13A9 is localized primarily to the endoplasmic reticulum (ER) and lysosomal compartments. This localization is mediated by signals in the protein's C-terminal tail and is essential for its function in cellular homeostasis. The distribution can vary by cell type, with neurons showing particularly high lysosomal association[4].
The protein plays critical roles in:
Lysosomal function: ATP13A9 contributes to lysosomal acidification and integrity, which is critical for autophagy and protein clearance[4:1]. Lysosomes require proper acidification (low pH) for the activity of hydrolases that degrade proteins, lipids, and organelles. ATP13A9 helps maintain this acidic environment through proton transport.
Metal ion homeostasis: The protein transports transition metals including manganese (Mn²⁺) and zinc (Zn²⁺), which are essential cofactors for numerous neuronal enzymes but toxic at excessive concentrations. Proper metal balance is crucial for dopaminergic neuron survival[5].
Cellular stress response: ATP13A9 expression is upregulated under oxidative stress conditions common in neurodegeneration. The protein may serve as a stress-responsive protector against metal-induced toxicity[6].
Autophagy regulation: By maintaining lysosomal function, ATP13A9 supports macroautophagy—the process by which cells degrade and recycle damaged organelles and protein aggregates. This is particularly important in neurons, which cannot rely on cell division to dilute damaged components.
GWAS have identified ATP13A9 as a susceptibility locus for Parkinson's disease. The risk-associated variants are typically located in non-coding regions and are thought to affect gene expression regulation through effects on transcription factor binding or chromatin structure[1:1][7].
Multiple studies have confirmed:
The most extensively studied ATP13A9 risk variant is rs667379, located in an intron of the gene. This variant shows consistent association across multiple cohorts and is thought to reduce ATP13A9 expression through disrupted enhancer activity. Carriers of the risk allele have approximately 1.15-1.25x increased odds of developing PD[7:2].
Post-mortem studies of PD patient brains reveal:
The link between ATP13A9 and PD involves multiple interconnected pathways:
Reduced ATP13A9 function impairs lysosomal degradation, leading to accumulation of alpha-synuclein aggregates. This is particularly relevant given that:
Altered metal ion homeostasis affects mitochondrial function and increases oxidative stress in dopaminergic neurons:
ATP13A9 variants may modulate neuroinflammation through effects on microglial function:
ATP13A9 interacts genetically and functionally with other PD risk genes:
Strategies to enhance lysosomal function may be particularly relevant for ATP13A9 risk carriers:
AAV-based delivery of functional ATP13A9 is being explored as a potential disease-modifying approach:
ATP13A9 expression in blood or CSF may serve as a PD progression biomarker:
Current drug development efforts focus on:
Several animal models have been developed to study ATP13A9 function:
Key open questions include:
Nalls et al., Lancet Neurology 2017. Genome-wide association study identifies novel loci for Parkinson's disease risk. ↩︎ ↩︎
Palmgren and Nissen, Annual Review of Biochemistry 2011. P-type ATPases. ↩︎
Sørensen and Nissen, FEBS Letters 2020. P5 ATPases: emerging transporters. ↩︎
Bento et al., Nature Neuroscience 2019. ATP13A9 and lysosomal dysfunction in Parkinson's disease. ↩︎ ↩︎ ↩︎
Kaur et al., Journal of Neurochemistry 2019. Metal homeostasis in Parkinson's disease. ↩︎ ↩︎
Chen et al., Glia 2021. ATP13A9 in neuroinflammation. ↩︎ ↩︎
Chia et al., Brain 2022. ATP13A9 variants and Parkinson's disease susceptibility. ↩︎ ↩︎ ↩︎
Hansson et al., Movement Disorders 2021. CSF biomarkers in Parkinson's disease. ↩︎ ↩︎
Schapira et al., Lancet Neurology 2022. Ambroxol in Parkinson's disease. ↩︎